Guibal FC*, Alberich-Jorda M*, Hirai H, Ebralidze A, Levantini E, Di Ruscio A, Zhang P, Santana-Lemos BA, Neuberg D, Wagers AJ, Rego EM, Tenen DG (*: equally contributed): Identification of a myeloid committed progenitor as the cancer initiating cell in acute promyelocytic leukemia. Blood. 114(27): 5415-25, 2009.
Okamoto M, Hirai H, Taniguchi K, Shimura K, Inaba T, Shimazaki C, Taniwaki M, Imanishi J: Toll-like Receptors (TLRs) are expressed by myeloid leukaemia cell lines, but fail to trigger differentiation in response to the respective TLR ligands. Br J Haematol. 147(4): 585-7, 2009.
Ashihara E, Kawata E, Nakagawa Y, Shimazaki C, Kuroda J, Taniguchi K, Uchiyama H, Tanaka R, Yokota A, Takeuchi M, Kamitsuji Y, Inaba T, Taniwaki M, Kimura S, Maekawa T: β-catenin small interfering RNA successfully suppressed progression of multiple myeloma in a mouse model. Clin Cancer Res, 15(8); 2731-2738, 2009.
Tsubakimoto Y, Yamada H, Yokoi H, Kishida S, Takata H, Kawahito H, Matsui A, Urao N, Nozawa Y, Hirai H, Imanishi J, Ashihara E, Maekawa T, Takahashi T, Okigaki M, Matsubara H: Bone marrow angiotensin AT1 receptor regulates differentiation of monocyte lineage progenitors from hematopoietic stem cells. Arterioscler Thromb Vasc Biol. 29(10): 1529-36, 2009.
平位秀世: C/EBP family 転写因子による顆粒球造血の制御. 第15回 血液科学セミナー, 東京, 2009.
学会発表
Hirai H, Kamio N, Matsusue A, Ogino S, Kimura N, Satake S, Ashihara E, Maekawa T, Tenen DG, Imanishi J: CREB Is Involved in the Regulation of C/EBPβ; During 'emergency' Granulopoiesis. The American Society of Hematology 51st Annual Meeting and Exposition, New Orleans, 2009.
Sakai K, Kawata E, Ashihara E, Yamauchi A, Kimura S, Hirai H, Hirashima M, Yoshimura N, Maekawa T: Galectin-9 Ameriorates Acute GVHD by Inducing T-cell Apoptosis and Increasing Regulatory T cell. The American Society of Hematology 51st Annual Meeting and Exposition, New Orleans, 2009.
Tanaka R, Kimura S, Hosomi T, Hirai M, Nagao R, Yokota A, Takeuchi M, Yao H, Sakai K, Adachi S, Hirai H, Ashihara E, Maekawa T: Automated and Rapid Detection of BCR-ABL Kinase Domain Mutations in IM Resistant Patients with Ph+ Leukemias. The American Society of Hematology 51st Annual Meeting and Exposition, New Orleans, 2009.
Nagao R, Ashihara A, Kimura S, Yao H, Takeuchi M, Yokota A, Tanaka R, Hirai H, Strovel JW, Padia J, Cholody WM, Maekawa T: Inhibition of Wnt/β-Catenin Signaling by AV65 Treatment Caused Cell Cycle Arrest and Induced Caspase-Independent or -Dependent Apoptosis in CML Cells. The American Society of Hematology 51st Annual Meeting and Exposition. New Orleans, 2009.
Yao H, Ashihara A, Nagao R, Kimura S, Hirai H, Strovel JW, Padia J, Cholody WM, Maekawa T: AV-65, a Novel Inhibitor of the Wnt/β-catenin Signaling Pathway, Inhibits the Proliferation of Myeloma Cells. The American Society of Hematology 51st Annual Meeting and Exposition, New Orleans, 2009.
Huang G*, Zhang P*, Hirai H, Elf S, Yan X, Chen Z, Koschmieder S, Okuno Y, Dayaram T, Growney JD, Shivdasani RA, Gilliland DG, Speck NA, Nimer SD, Tenen DG ((*: equally contributed)): PU.1 is a major downstream target of AML (RUNX1) in adult mouse hematopoiesis. Nature Genetics, 40(1): 51-60, 2008.
Fuchida SI, Shimazaki C, Hirai H, Akamatsu S, Yamada N, Uchida R, Okano A, Okamoto M, Inaba T, Taniwaki M: The effects of thalidomide on chemotactic migration of multiple myeloma cell lines. Int J Lab Hematol, 30(3), 220-229, 2008.
Kawata E, Ashihara E, Kimura S, Takenaka K, Sato K, Tanaka R, Yokota A, Kamitsuji Y, Takeuchi M, Kuroda J, Tanaka F, Yoshikawa T, Maekawa T: Administration of PLK-1 siRNA with atelocollagen prevents the growth of liver metastases of lung cancer. Mol Cancer Ther, 7(9); 2904-2912, 2008.
Kuroda J, Kimura S, Andreeff M, Ashihara E, Kamitsuji Y, Yokota A, Kawata E, Takeuchi M, Tanaka R, Murotani Y, Matsumoto Y, Tanaka H, Strasser A, Taniwaki M, Maekawa T: ABT-737 is a useful component of combinatory chemotherapies for chronic myelogenous leukaemias with diverse drug resistance mechanisms. Br J Haematol, 140(2); 181-190, 2008.
Tanaka R, Kuroda J, Stevenson W, Ashihara E, Ishikawa T, Taki T, Kobayashi Y, Kamitsuji Y, Kawata E, Takeuchi M, Murotani Y, Yokota A, Hirai M, Majima S, Taniwaki M, Maekawa T, Kimura S: Fully automated and super-rapid system for the detection of JAK2V617F mutation. Leuk Res, 32(9); 1462-1467, 2008.
Kuroda J, Kamitsuji Y, Kimura S, Ashihara E, Nakagawa Y, Kawata E, Takeuchi M, Murotani Y, Yokota A, Tanaka R, Andreeff M, Taniwaki M, Maekawa T: Anti-myeloma effect of Homoharringtonine with concomitant targeting of multiple myeloma-promoting molecules, Mcl-1, XIAP and b-catenin. Int J Hematol, 87(5); 507-15, 2008.
総説
Yokota A, Kimura S. Novel Agents to Override Imatinib Resistance Mechanisms. Drug Development Research, 69; 398-406, 2008.
学会発表
Okuda K, Harakawa N, VanEtten RA, Patel N, Domae N, Sato Y and Hirai H: Distinct Transforming and Leukemogenic Activities of Tel-Arg and Tel-Abl Oncogenes in Mice: Possible Negative Role for the Transforming Activity in C-Terminus of Arg. 50th ASH Annual Meeting and Exposition, San Francisco, 2008.
Yokota A, Kimura S, Tanaka R, Nagao R, Sakai K, Yao H, Takeuchi M, Kawatani M, Osada H, Ashihara E, Maekawa T: Roles of Osteoclasts in Leukemic Cells. The American Society of Hematology, 50th Annual Meeting and Exposition, San Francisco, 2008.
Nagao R, Kimura S, Ashihara E, Takeuchi M, Tanaka R, Yokota A, Yao H, Strovel JW, Cholody WM, Maekawa T: A novel beta-catenin inhibitor, AV65 suppresses the growth of CML cell lines which acquire imatinib-resistance because of Abl kinase domain mutations including T315I and hypoxia-adaptation. The American Society of Hematology, 50th Annual Meeting and Exposition, San Francisco, 2008.
Tanaka R, Squires MS, Kimura S, Yokota A, Mallett K, Smyth T, Thompson NT, Nagao R, Yamauchi T, Ashihara E, Lyons JF, Maekawa T: Activity of the Multi-Targeted Kinase Inhibitor, AT9283 on Imatinib-Resistant CML Models. The American Society of Hematology, 50th Annual Meeting and Exposition, San Francisco, 2008.
田中瑠璃子, 木村晋也, 横田明日美, 芦原英司, 山内高弘, Mathew S Squires, Matthias Reule, Jeyne Curry, Kirsty Mallet, Murray Yule, Neil T Thompson, John F Lyons, 前川 平: 新規Auroraキナーゼ阻害剤AT9283のBCR-ABL/T315Iに対する効果. 第70回日本血液学会総会, 京都, 2008.
2007年
原著論文
Feinberg MW, Wara AK, Cao Z, Lebedeva MA, Rosenbauer F, Iwasaki H, Hirai H, Katz JP, Haspel RL, Gray S, Akashi K, Serge J, Kaestner KH, Tenen DG, Jain MK: The Kruppel-like factor KLF4 is a critical regulator of monocyte differentiation. EMBO J 26(18): 4138-48, 2007.
Kuroda J, Kimura S, Strasser A, Andreeff M, O’Reilly LA, Ashihara E, Kamitsuji Y, Yokota A, Kawata E, Takeuchi M, Tanaka R, Tabe Y, Taniwaki M, Maekawa T: Apoptosis-based dual molecular targeting by INNO-406, a second generation Bcr-Abl inhibitor, and ABT-737, an inhibitor of anti-apoptotic Bcl-2 proteins, against Bcr-Abl-positive leukemia. Cell Death Diff, 14(9); 1667-77, 2007.
Yokota A, Kimura S, Masuda S, Ashihara E, Kuroda J, Sato K, Kamitsuji Y, Kawata E, Deguchi Y, Urasaki Y, Terui Y, Ruthardt M, Ueda T, Hatake K, Inui K, Maekawa T: INNO-406, a novel BCR-ABL/Lyn dual tyrosine kinase inhibitor, suppresses the growth of Ph+ leukemia cells in the central nervous system and cyclosporine A augments its in vivo activity. Blood, 109(1); 306-314, 2007.
Kobayashi S, Costa DB, Hirai H, Halmos B, Sporn MB and Tenen DG: The C/EBP transcription factor as a therapeutic target in lung cancer. American Association for Cancer Research Annual Meeting, Los Angels, 2007.
Yokota A, Kimura S, Masuda T, Ashihara E, Urasaki Y, Terui Y, Ruthardt M, Ueda T, Hatake K, Inui K, Maekawa T: Anti-tumor Effect of INNO-406, a Novel Bcr-Abl Inhibitor in Combination with Cyclosporine A Against the Murine Central nervous System and Systemic Leukemia Model. The American Society of Hematology, 49th Annual Meeting and Exposition, Atlanta, 2007.
Ashihara E, Shimura K, Shimazaki C, Matsunaga S, Tanaka R, Yokota A, Murotani Y, Takeuchi M, Kawata E, Kamitsuji Y, Kuroda J, Taniwaki M, Kimura S, Maekawa T: Kinetics of Circulating Endothelial Progenitors in Patients with Sclerodermatous Chronic Graft-Versus Host Disease. The American Society of Hematology, 49th Annual Meeting and Exposition, Atlanta, 2007.
Kawata E, Ashihara E, Tanaka R, Yokota A, Murotani Y, Taniguchi M, Kamitsuji Y, Kuroda J, Inaba T, Shimazaki C, Kimura S, Maekawa T: β-catenin siRNA Successfully Suppressed the Progression of Multiple Myeloma in In Vivo Mouse Model. The American Society of Hematology, 49th Annual Meeting and Exposition, Atlanta, 2007.
奥田恵子, 原川奈梨, 堂前尚親, 平位秀世, 佐藤裕子, RICHARD VAN ETTEN: TEL-ARG により誘導されるマウス病態の解析 : TEL-ABL との比較検討. 第69回日本血液学会総会・第49回日本臨床血液学会総会, 横浜, 2007.
Hirai H, Zhang P, Dayaram T, Hetherington CJ, Mizuno S, Imanishi J, Akashi K, Tenen DG: C/EBPβ is required for 'emergency' granulopoiesis. Nat Immunol. 7(7): 732-9, 2006.
Asada H, Kishida T, Hirai H, Shin-Ya M, Imanishi J, Takeuchi M, Mazda O: Combination vaccine of dendritic cells (DCs) and T cells effectively suppressed preestablished malignant melanoma in mice. Cancer Lett. 240(1): 83-93, 2006.
Sato K, Yuasa T, Nogawa M, Kimura S, Segawa H, Yokota A, Maekawa T: A third generation bisphosphonate, minodronic acid (YM529), successfully prevented the growth of bladder cancer in vitro and in vivo. Br J Cancer, 95(10); 1354-61, 2006.
学会発表
Yokota A, Kimura S, Masuda T, Ashihara E, Urasaki Y, Terui Y, Ruthardt M, Ueda T, Hatake K, Inui K, Maekawa T: Cyclosporin A, a P-gp inhibitor, Augments the Anti-Central Nervous System Ph+ Leukemia Effects of INNO-406. The American Society of Hematology 48th Annual Meeting and Exposition, Orland, 2006.
Hirai H, Samokhvalov IM, Fujimoto T, Nishikawa S, Imanishi J, Nishikawa S: Involvement of Runx1 in the downregulation of fetal liver kinase-1 expression during transition of endothelial cells to hematopoietic cells. Blood. 106(6): 1948-55, 2005.
Shin-Ya M, Hirai H, Satoh E, Kishida T, Asada H, Aoki F, Tsukamoto M, Imanishi J, Mazda O: Intracellular interferon triggers Jak/Stat signaling cascade and induces p53-dependent antiviral protection. Biochem Biophys Res Commun. 329(3): 1139-46, 2005.
Kimura S, Naito H, Segawa H, Kuroda J, Yuasa T, Sato K, Yokota A, Kamitsuji Y, Kawata E, Ashihara E, Nakaya Y, Naruoka H, Wakayama T, Nasu K, Asaki T, Niwa T, Hirabayashi K, Maekawa T: NS-187, a potent and selective dual Bcr-Abl/Lyn tyrosine kinase inhibitor, is a novel agent for imatinib-resistant leukemia. Blood, 106(12); 3948-3954, 2005.
Segawa H, Kimura S, Kuroda J, Sato K, Yokota A, Kawata E, Kamitsuji Y, Ashihara E, Yuasa T, Fujiyama Y, Ottmann OG, Maekawa T: Zoledronate synergizes with imatinib mesylate to inhibit Ph+ primary leukaemic cell growth. Br J Haematol, 130(4); 558-560, 2005.
Nogawa M, Yuasa T, Kimura S, Kuroda J, Segawa H, Sato K, Yokota A, Koizumi M, Maekawa T: Zoledronic acid mediates Ras-independent growth inhibition of prostate cancer cells. Oncol Res, 15(1); 1-9, 2005.
Nogawa M, Yuasa T, Kimura S, Tanaka M, Kuroda J, Sato K, Yokota A, Segawa S, Toda Y, Kageyama S, Yoshiki T, Okada Y, Maekawa T: Intravesical administration of small interfering RNA targeting PLK-1 successfully prevents the growth of bladder cancer. J Clin Invest, 115(4); 978-985, 2005.
Sato K, Kimura S, Segawa H, Yokota A, Matsumoto S, Kuroda J, Nogawa M, Yuasa T, Kiyono Y, Wada H, Maekawa T: Cytotoxic effects of γδ T cells expanded ex vivo by a third generation bisphosphonate for cancer immunotherapy. Int J Cancer, 116(1); 94-99, 2005.
Yuasa T, Nogawa M, Kimura S, Yokota A, Sato K, Segawa H, Kuroda J, Maekawa T: A third generation bisphosphonate, minodronic acid (YM529), augments the interferon α/β-mediated inhibition of renal cell cancer cell growth both in vitro and in vivo. Clin Cancer Res, 11; 853-859, 2005.
Segawa H, Kimura S, Kuroda J, Sato K, Nogawa M, Yuasa T, Yokota A, Hodohara K, Fujiyama Y, Maekawa T. The anti-leukemic efficacy of the third generation bisphosphonate ONO5920/YM529. Leuk Res, 29(4); 451-457, 2005.
学会発表
Zhang P, Iwasaki H, Hirai H, Akashi K and Tenen DG: Regulation of hematopoietic stem cells by myeloid transcription factor. Wilsede Meeting Modern Trends in Human Leukaemia, Wilsede, 2005.
Yokota A, Kimura S, Oyama T, Ashihara E, Naito H, Ueda T, Hatake K, Hirabayashi K Maekawa T: Anti-tumor activity of a novel Bcr-Abl/Lyn dual inhibitor, NS-187, in murine CNS Ph+ leukemia models. The American Society of Hematology 47th Annual Meeting and Exposition, Atlanta, 2005.
Kimura S, Naito H, Yokota A, Kawata E, Ashihara E, Nakaya Y, Naruoka H, Wakayama T, Asaki T, Niwa T, Hirabayashi K, Maekawa T: A dual Bcr-Abl/Lyn tyrosine kinase inhibitor, NS-187, Is a novel agent for imatinib-resistant leukemia. The American Society of Hematology 47th Annual Meeting and Exposition, Atlanta, 2005.
Oji Y, Suzuki M, Nakano Y, Maruno M, Nakatsuka S, Jomgeow T, Abeno S, Tatsumi N, Yokota A, Aoyagi S, Nakazawa T, Ito K, Kanato K, Shirakata T, Nishida S, Hosen N, Kawakami M, Tsuboi A, Oka Y, Aozasa K, Yoshimine T, Sugiyama H: Overexpression of the Wilms’ tumor gene WT1 in primary astrocytic tumors. Cancer Sci, 95(10); 822-827, 2004.
Oji Y, Nakamori S, Fujikawa M, Nakatsuka S, Yokota A, Tatsumi N, Abeno S, Ikeba A, Takashima S, Tsujie M, Yamamoto H, Sakon M, Nezu R, Kawano K, Nishida S, Ikegame K, Kawakami M, Tsuboi A, Oka Y, Yoshikawa K, Aozasa K, Monden M, Sugiyama H: Overexpression of the Wilms’ tumor gene WT1 in pancreatic ductal adenocarcinoma. Cancer Sci, 95(7); 583-587, 2004.
学会発表
Asada H, Kishida T, Hirai H, Imanishi J, Mazda O: Dendritic Cell (DC) Vaccine Loaded with Apoptotic Tumor Fragments Effectively Suppress Preestablished Malignant Melanoma in Mice. American Society of Gene Therapy 7th Annual Meeting, Minneapolis, 2004.
Hirai H, Ogawa M, Suzuki N, Yamamoto M, Breier G, Mazda O, Imanishi J, Nishikawa S: Hemogenic and nonhemogenic endothelium can be distinguished by the activity of fetal liver kinase (Flk)-1 promoter/enhancer during mouse embryogenesis. Blood. 101(3): 886-93, 2003.
Yurugi-Kobayashi T, Itoh H, Yamashita J, Yamahara K, Hirai H, Kobayashi T, Ogawa M, Nishikawa S, Nishikawa S, Nakao K: Effective contribution of transplanted vascular progenitor cells derived from embryonic stem cells to adult neovascularization in proper differentiation stage. Blood. 101(7): 2675-8, 2003.
Oji Y, Miyoshi Y, Koga S, Nakano Y, Ando A, Nakatsuka S, Ikeba A, Takahashi E, Sakaguchi N, Yokota A, Hosen N, Ikegame K, Kawakami M, Tsuboi A, Oka Y, Ogawa H, Aozasa K, Noguchi S, Sugiyama H: Overexpression of the Wilms’ tumor gene WT1 in primary thyroid cancer. Cancer Sci, 94(7); 606-611, 2003.
Shin-Ya M, Mazda O, Tsuchihara C, Hirai H, Imanishi J, Takeuchi M: Interleukin-2 abolishes myeloid cell accumulation induced by Lewis lung carcinoma. J Interferon Cytokine Res. 23(11): 631-8, 2003.
2002年
原著論文
Asada H, Kishida T, Hirai H, Satoh E, Ohashi S, Takeuchi M, Kubo T, Kita M, Iwakura Y, Imanishi J, Mazda O: Significant antitumor effects obtained by autologous tumor cell vaccine engineered to secrete interleukin (IL)-12 and IL-18 by means of the EBV/lipoplex. Mol Ther. 5 (5 Pt 1): 609-16, 2002.
Ochiai N, Shimazaki C, Inaba T, Fuchida S, Okano A, Hatsuse M, Hirai H, Ashihara E, Fujita N, Nakagawa M: Effect of vinorelbine on the growth of human myeloma cell lines in vitro. Leuk Res. 26(8): 731-8, 2002.
Ochiai N, Shimazaki C, Okano A, Hatsuse M, Takahashi R, Hirai H, Ashihara E, Inaba T, Fujita N, Nakagawa M: Meningeal relapse after double peripheral blood stem cell transplantation in IgD myeloma. Leuk Lymphoma. 43(3): 641-3, 2002.
Hirai H, Ogawa M, Imanishi J, Nishikawa SI: Prospective distinction between hemogenic and non-hemogenic endothelium by the activity of fetal liver kinase (Flk)-1 promoter/enhancer during mouse embryogenesis. The American Society of Hematology 44th Annual Meeting, Philadelphia, 2002.
Asada H, Kishida T, Satoh E, Hirai H, Imanishi J, Mazda O: The Epstein-Barr virus (EBV)/lipoplex-mediated transfection of interleukin (IL)-12 and IL-18 genes augments T helper 1 (Th1) immune responses and therapeutic anti-melanoma effects of autologous tumor vaccine. 5th Annual Meeting of the American Society of Gene Therapy, Boston, 2002.
2001年
原著論文
Ashihara E, Shimazaki C, Hirai H, Inaba T, Hasegawa G, Mori S, Nakagawa M：Human herpes virus 8-negative primary effusion lymphoma in a patient with a ventriculoperitoneal shunt tube. Int J Hematol. 74(3): 327-32, 2001.
Sakatani T, Shimazaki C, Hirai H, Okano A, Hatsuse M, Okamoto A, Takahashi R, Ashihara E, Inaba T, Yokota H, Nakahara K, Hirai H, Nakagawa M: Early relapse after high-dose chemotherapy rescued by tumor-free autologous peripheral blood stem cells in acute lymphoblastic leukemia: importance of monitoring for WT1-mRNA quantitatively. Leuk Lymphoma. 42(1-2): 225-9, 2001.
Hirai H, Shimazaki C, Hatsuse M, Okano A, Ashihara E, Inaba T, Murakami S, Saigo K, Nakagawa M: Autologous peripheral blood stem cell transplantation for adult patients with B-cell lymphoma-associated hemophagocytic syndrome. Leukemia. 15(2): 311-2, 2001.
Takahashi R, Shimazaki C, Inaba T, Okano A, Hatsuse M, Okamoto A, Hirai H, Ashihara E, Nakagawa M: A newly developed bisphosphonate, YM529, is a potent apoptosis inducer of human myeloma cells. Leuk Res. 25(1): 77-83, 2001.
Shimazaki C, Inaba T, Okano A, Hatsuse M, Takahashi R, Hirai H, Sudo Y, Ashihara E, Adachi Y, Murakami S, Saigo K, Tsuda H, Fujita N, Nakagawa M: Clinical characteristics of B-cell lymphoma-associated hemophagocytic syndrome (B-LAHS): comparison of CD5+ with CD5- B-LAHS. Intern Med. 40(9): 878-82, 2001.
Kishida T, Asada H, Satoh E, Tanaka S, Shinya M, Hirai H, Iwai M, Tahara H, Imanishi J, Mazda O: In vivo electroporation-mediated transfer of interleukin-12 and interleukin-18 genes induces significant antitumor effects against melanoma in mice. Gene Ther. 8(16): 1234-40, 2001.
Shimura K, Shimazaki C, Okano A, Hatsuse M, Okamoto A, Takahashi R, Hirai H, Sumikuma T, Ashihara E, Inaba T, Fujita N, Yasuda J, Nakagawa M: Therapy-related myeloid leukemia following platinum-based chemotherapy for ovarian cancer. Japanese Journal of Clinical Hematology. 42(2): 99-103, 2001.
2000年
原著論文
Kikuta T, Shimazaki C, Ashihara E, Sudo Y, Hirai H, Sumikuma T, Yamagata N, Inaba T, Fujita N, Kina T, Nakagawa M: Mobilization of hematopoietic primitive and committed progenitor cells into blood in mice by anti-vascular adhesion molecule-1 antibody alone or in combination with granulocyte colony-stimulating factor. Exp Hematol. 28(3): 311-7, 2000.
Inaba T, Shimazaki C, Sumikuma T, Okamoto A, Shimura K, Takahashi R, Hirai H, Ashihara E, Hibi S, Fujita N, Yoshimura M, Nakagawa M: CD45-negative acute leukemia in adulthood. Eur J Haematol. 64(1): 66-7, 2000.
Tanaka S, Iwai M, Harada Y, Morikawa T, Muramatsu A, Mori T, Okanoue T, Kashima K, Maruyama-Tabata H, Hirai H, Satoh E, Imanishi J, Mazda O: Targeted killing of carcinoembryonic antigen (CEA)-producing cholangiocarcinoma cells by polyamidoamine dendrimer-mediated transfer of an Epstein-Barr virus (EBV)-based plasmid vector carrying the CEA promoter. Cancer Gene Ther. 7(9): 1241-50, 2000.
Harada Y, Iwai M, Tanaka S, Okanoue T, Kashima K, Maruyama-Tabata H, Hirai H, Satoh E, Imanishi J, Mazda O: Highly efficient suicide gene expression in hepatocellular carcinoma cells by epstein-barr virus-based plasmid vectors combined with polyamidoamine dendrimer. Cancer Gene Ther. 7(1): 27-36, 2000.
Hatsuse M, Okano A, Okamoto A, Shimura K, Takahashi R, Hirai H, Ashihara E, Inaba T, Fujita N, Shimazaki C, Nakagawa M: Autologous transplantation of Ph-negative peripheral blood stem cells for treatment of chronic myelogenous leukemia. Japanese Journal of Clinical Hematology. 41(8):671-5, 2000.
Shimura K, Shimazaki C, Okamoto A, Takahashi R, Hirai H, Sumikuma T, Ashihara E, Inaba T, Fujita N, Komatsu S, Hirano S, Nakagawa M: Werner's syndrome associated with acute myelofibrosis. Japanese Journal of Clinical Hematology. 41(2):123-8, 2000.
学会発表
Harada Y, Iwai M, Tanaka S, Morikawa T, Muramatsu A, Mori T, Okanoue T, Kashima K, Hirai H, Satoh E, Imanishi J, Mazda O: Gene therapy for hepatocellular carcinoma in vivo by EBV-based plasmid vector-mediated transfer of the Herpes simplex virus thymidine kinase gene. The American Society of Gene Therapy, 3rd Annual Meeting, Denver, 2000.